Skip to content

Lp-PLA2 Activity

Also called Lipoprotein-associated phospholipase A2, PLAC test

An enzyme produced by inflammatory cells inside arterial plaque — a marker of vascular-specific inflammation rather than general body-wide inflammation.

  • Lab price$60.00
  • Retest6–12 months after intervention

Normal is not optimal

hs-CRP tells you there's inflammation somewhere; Lp-PLA2 tells you it's happening in your artery walls. That specificity makes it useful for refining risk when ApoB is borderline or family history is strong.

Ranges
Standard
Same; runs slightly lower in women
Optimal
Under 225 nmol/min/mL; the same cohort used 200 for women.

Check your own Lp-PLA2 Activity number

Order it yourself

One test, drawn at a Quest lab near you. The price is the lab’s, from Marek’s own menu.

Lp-PLA2 Activity test
Marek Diagnostics · single test, drawn at Quest
$60.00
Code CAMERON
Order this test

Code CAMERON takes 10% off. Marek’s checkout adds its one-time blood-draw fee to individual tests and shows the total before you pay.

Order it with ApoB (Apolipoprotein B) and Lipoprotein(a) — Lp(a) (3 tests, one cart)

What moves Lp-PLA2 Activity

Active plaque inflammation, elevated ApoB/LDL particles, smoking, insulin resistance, and genetics.

If it’s high: Suggests inflamed, potentially unstable plaque — associated with higher stroke and coronary event risk independent of LDL.

If it’s low: Favorable.

A reasonable add-on for anyone with elevated ApoB or Lp(a) who wants to know whether plaque is actively inflamed — particularly long-term androgen users.
The Before-You-Stack Lab Kit cover

The free Before‑You‑Stack Lab Kit

The 12 labs I’d run before any protocol, what each one tells you, add-ons by goal and how to order them yourself. The PDF is yours straight away.

After that it is about two emails a week: a marker, a compound or a protocol. Unsubscribe in one click.

Everything else about Lp-PLA2 Activity

What can skew the result

2 things can change the reading or the real level

Some change your real level; others only change the reading. Each one says which, and what to do about it.

Acute illness or infectionPhysiological state

This is an acute-phase reactant — it moves substantially during any infection, injury or inflammatory episode, and the change has nothing to do with your baseline.

Do this: Wait two weeks after any illness, vaccination or injury before drawing or interpreting.

A real change — retest once it passes
StatinsDrug or supplement

Lower Lp-PLA2 alongside lipids, so a treated value understates untreated vascular inflammation.

Do this: Interpret with treatment status in mind.

A real change — account for the cause

Symptoms it helps explain

1 symptom, and which to test first

Then worth checking for

  • Heart disease or stroke runs in my family

Plan of attack

What to do, in this order
  1. Confirm the number is real

    Acute illness or infection. This is an acute-phase reactant — it moves substantially during any infection, injury or inflammatory episode, and the change has nothing to do with your baseline. Wait two weeks after any illness, vaccination or injury before drawing or interpreting.

  2. Read it with its partner

    Interpret with ApoB and hs-CRP; it refines rather than replaces them. Draw it alongside: ApoB (Apolipoprotein B), Lipoprotein(a) — Lp(a), hs-CRP (High-Sensitivity C-Reactive Protein).

  3. Work out which direction is yours

    If it's high — Suggests inflamed, potentially unstable plaque — associated with higher stroke and coronary event risk independent of LDL.

  4. Fix it in order: food, then cause, then everything else

    Nutrition. Reduce saturated fat, increase soluble fiber and omega-3s, Mediterranean pattern, lose visceral fat.
    Lifestyle. Stop smoking (a major driver), aerobic exercise, blood pressure control.

  5. Retest

    6–12 months after intervention. Change one thing at a time, or the retest can't tell you which thing worked.

Where the optimal range comes from

Outcome-anchored optimum

Outcome-anchored optimum. A target drawn from what happened to people at that level — not from the middle of a lab's reference population.

The number
Under 225 nmol/min/mL on the activity (PLAC) assay is the manufacturer's cleared cut-point. The cohort it was validated in used sex-specific thresholds instead: 250 nmol/min/mL in men and 200 in women, each the 80th percentile of its sex.
Measured in
REGARDS case-cohort — 5,025 US adults, 771 with incident coronary heart disease and 4,254 without.
Anchored to
Incident coronary heart disease. The sex-specific 80th-percentile cut-points are what the risk estimate was actually built on.
Source
PLAC test review, American Family Physician 2020, reporting the REGARDS validation.

The site previously printed <200 for men and <175 for women here. Neither number had a source and both have been removed. The AFP review is blunt about the limits of any single cut-point: the binary cut-off is neither sensitive nor specific, and a single threshold ignores a documented sex difference. Use it as a tiebreaker when ApoB and hs-CRP disagree — not as a primary screen.

What Lp-PLA2 Activity measures

And why people check it

What it tells you

An enzyme produced by inflammatory cells inside arterial plaque — a marker of vascular-specific inflammation rather than general body-wide inflammation.

Why people check it

hs-CRP tells you there's inflammation somewhere; Lp-PLA2 tells you it's happening in your artery walls. That specificity makes it useful for refining risk when ApoB is borderline or family history is strong.

What Lp-PLA2 Activity means next to other markers

1 pattern worth knowing
Cholesterol treated, inflammation ignored

hs-CRP elevated · ApoB at target · Lp-PLA2 or MPO raised

Residual inflammatory risk. Plaque forms and destabilizes through inflammation as well as lipids, so hitting an ApoB target while CRP stays high leaves a meaningful part of the risk untouched.

Rule out the obvious first — CRP rises with any infection, injury or hard training, so retest rested and well. If it stays up: sleep, visceral fat, periodontal disease, gut health, omega-3s. Persistent unexplained elevation deserves a real workup.

Panels that carry Lp-PLA2 Activity

2 panels, prices with code CAMERON

Read it alongside

Related markers, goals and what moves it in the library

The deep read, with sources

What the Lp-PLA2 Activity test actually measures, and the references

What Lp-PLA2 Activity actually measures — the analyte, and the assay

This is an enzyme test wearing a lipid test's clothes. Lp-PLA2 is a 45 kDa calcium-independent phospholipase, the product of the PLA2G7 gene, secreted mostly by macrophages and monocytes. Its other name is platelet-activating factor acetylhydrolase, and the two names describe the same protein doing the same job: cleaving the sn-2 ester of a phospholipid. On an oxidized LDL particle that cut releases lysophosphatidylcholine and an oxidized free fatty acid, which is the step the atherosclerosis argument rests on Zhang 2022.

Roughly 80% of it is riding on LDL, the rest on HDL and Lp(a). That matters more than it sounds: the enzyme has no free circulation of its own, so a fall in LDL particle number lowers the measured value without a single macrophage changing behavior.

Two completely different tests are sold under this one name, and the units are how you tell them apart. A mass assay is an immunoassay: it counts enzyme protein and reports ng/mL. An activity assay is a kinetic reaction: it puts your plasma with a synthetic substrate, watches how fast the ester bond falls apart, and reports nmol/min/mL. One measures how much enzyme is present, the other how much work it does. They are not two calibrations of one number and there is no conversion factor. The version cleared for cardiovascular risk in the United States, and the one this marker's 225 nmol/min/mL line belongs to, is the activity assay.

Genetics treats them as separate traits, which is the strongest evidence they are. A meta-analysis of genome-wide studies across five community-based cohorts looked for loci associated with variation in Lp-PLA2 mass and Lp-PLA2 activity and reported eight, analyzing the two as distinct measurements throughout Grallert 2012.

Even within the activity assay, the instrument used to matter. Results were not interchangeable between analyzers until a recombinant enzyme calibrator was evaluated as a way of harmonizing them Cerelli 2016. A number from 2014 and a number from a different platform today are not automatically the same measurement.

Lp-PLA2 Activity: what changes the blood, and what only changes the reading

What changes the enzyme in your blood — strongest lever first:

  1. ApoB particle number. The enzyme is cargo. Cut LDL particles with a statin and the measured activity falls, because you removed the vehicles, not because you calmed the macrophage. This is the single commonest misreading of a repeat result.
  2. Your PLA2G7 genotype. Loss-of-function variants exist and are common in some East Asian populations; a carrier can run an activity near the floor of the assay for life with no vascular meaning at all Grallert 2012.
  3. Macrophage burden in plaque and elsewhere. The enzyme is secreted by the same cell population that accumulates in an inflamed arterial wall Zhang 2022.
  4. Smoking, visceral adiposity and insulin resistance, all of which raise it and all of which also raise apoB — so the effect arrives twice.
  5. Sex. Women run lower, which is why the original validation work used sex-specific percentiles rather than one line.
  6. Direct enzyme inhibition. Darapladib suppressed activity profoundly and did nothing else useful, which is the subject of this page's limits section White 2014.

What changes only the reading:

  1. Which of the two assays was run. A mass result in ng/mL compared against an activity cut-point in nmol/min/mL is not a high or low value; it is a category error. Check the unit on the report before anything else.
  2. Which analyzer, and when. Harmonization of activity results between instruments needed a recombinant enzyme calibrator to be evaluated for the purpose Cerelli 2016; results predating that work are not automatically comparable with results after it.
  3. Sample handling. An activity assay measures catalysis, so it is sensitive to things a protein immunoassay shrugs off — delayed separation, repeated freeze-thaw, storage temperature.
  4. Gross lipemia, which loads the reaction with competing substrate and interferes optically.
  5. A changed cut-point. The threshold printed beside the result has been revised commercially; two reports carrying the same activity value can carry different flags.

Reference interval or decision threshold — which kind of number Lp-PLA2 Activity is

225 nmol/min/mL is a decision threshold, and it is not even a physiological one. It is the line the cleared test uses to sort people into higher and lower predicted risk. It was not derived by asking what value keeps an artery healthy; it was derived from where people sat in a distribution and what happened to them afterwards.

The validation work used two lines, not one. The cohort behind the cut-point worked from sex-specific 80th percentiles — around 250 nmol/min/mL for men and 200 for women — and the single marketed number sits between them. A woman at 215 is above her own cohort's 80th percentile and below the printed line. That is a property of the rounding, not of her arteries.

A percentile is a statement about a crowd. The 80th percentile means one person in five was higher. It carries no claim that the other four are safe, and no claim that moving from the 81st percentile to the 79th changes anything.

There is no reference interval here in the usual sense, because the test was never positioned as a health measure with a normal band. It was positioned as a risk stratifier, which is why the report prints one number and a direction rather than a range with two ends.

How you would know your Lp-PLA2 Activity was wrong — and when to redraw

The clock belongs to the particle, not the enzyme. An LDL particle circulates for roughly 2 to 4 days before clearance, and the enzyme on it goes with it. So a real change in Lp-PLA2 activity follows a real change in apoB within weeks, and there is no biological reason to redraw sooner. 6 to 12 weeks after a lipid intervention has reached steady state is the honest interval.

Conditions the second draw has to match: the same assay type — activity for activity — the same laboratory and platform Cerelli 2016, comparable fasting state, and no acute illness in the preceding fortnight.

What would have to change for the second number to mean anything. Lp-PLA2 alone cannot tell you which of two things happened, and the companion test decides it:

  • Draw an ApoB beside it every time. If activity fell and apoB fell in proportion, you removed carriers. If activity fell and apoB did not move, something changed about the enzyme itself. Those are different results and the Lp-PLA2 number cannot separate them.
  • An hs-CRP tests the inflammation story. A falling Lp-PLA2 with a static hs-CRP is not an anti-inflammatory response.
  • An Lp(a) explains a stubborn value, since Lp(a) carries the enzyme too and does not respond to the levers that move LDL.
  • A floor-level result should prompt a question, not a celebration. An activity near the bottom of the assay in someone with unremarkable lipids is more likely to be genotype than achievement Grallert 2012.

What Lp-PLA2 Activity cannot tell you

It cannot tell you that lowering it will help you, and the largest test of that idea said the opposite. Darapladib is a direct Lp-PLA2 inhibitor. In 15,828 patients with stable coronary disease followed a median 3.7 years, the primary endpoint occurred in 769 of 7,924 (9.7%) on darapladib and 819 of 7,904 (10.4%) on placebo — hazard ratio 0.94, 95% CI 0.85 to 1.03, P = 0.20 White 2014. A later pharmacogenetic meta-analysis pooled the baseline risk factors, pharmacodynamics, efficacy and tolerability of two large outcome trials of the drug Yeo 2017. Suppressing the enzyme did not deliver the events benefit the marker predicted. That is the definition of a risk marker rather than a causal target, and it is the most important sentence on this page.

It cannot separate itself from your LDL. Because most of the enzyme rides on apoB particles, a large part of any Lp-PLA2 result is a restatement of information ApoB already gave you. The independent signal is the part that is left after that, and it is smaller than the test's marketing implies.

It cannot localize anything. There is no plaque, no artery and no side of the body in this number. A high value does not indicate where; imaging does that and blood does not.

It cannot be compared with somebody else's result unless both came from the same kind of assay on a harmonized platform Cerelli 2016, which is exactly the comparison people make in forums and comment sections.

The wrong inference readers actually draw is that a falling Lp-PLA2 on a statin proves the statin calmed vascular inflammation. It proves there are fewer LDL particles to carry enzyme. Whether the wall quieted down is a question hs-CRP and imaging answer, not this one.

Sources read for these sections

  • White HD, et al. Darapladib for preventing ischemic events in stable coronary heart disease. New England Journal of Medicine 2014 · PMID 24678955
  • Yeo A, et al. Pharmacogenetic meta-analysis of baseline risk factors, pharmacodynamic, efficacy and tolerability endpoints from two large global cardiovascular outcomes trials for darapladib. PLoS One 2017 · PMID 28753643
  • Cerelli MJ, et al. Evaluation of recombinant enzyme calibration to harmonize lipoprotein-associated phospholipase A2 activity results between instruments. Clinical Biochemistry 2016 · PMID 26656641
  • Grallert H, et al. Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies. European Heart Journal 2012 · PMID 22003152
  • Zhang S, et al. Biological Properties and Clinical Significance of Lipoprotein-Associated Phospholipase A2 in Ischemic Stroke. Cardiovascular Therapeutics 2022 · PMID 36313479

Lp-PLA2 Activity questions

6 answered
What is a normal Lp-PLA2 Activity level?
Women: Same; runs slightly lower in women. Men: <225 nmol/min/mL. Ranges vary by laboratory and assay; always compare to the range printed on your own report.
What is the optimal Lp-PLA2 Activity level?
Women: Under 225 nmol/min/mL; the same cohort used 200 for women. Men: Under 225 nmol/min/mL — the cleared PLAC cut-point. The validation cohort used 250 for men, its sex-specific 80th percentile. PLAC test review, American Family Physician 2020, reporting the REGARDS validation.
What does a high Lp-PLA2 Activity mean?
Suggests inflamed, potentially unstable plaque — associated with higher stroke and coronary event risk independent of LDL.
What does a low Lp-PLA2 Activity mean?
Favorable.
How often should I retest Lp-PLA2 Activity?
6–12 months after intervention.
How do I test Lp-PLA2 Activity?
Through Marek Diagnostics without a doctor's visit, drawn at a Quest Diagnostics location in the US. Code CAMERON applies 10% off automatically through the links on this page.

Sources: Lp-PLA2 Studies Collaboration, Lancet 2010 — Lp-PLA2 and vascular risk.

Inside Skool · $10/mo

The Real Cardiovascular Risk protocol is a lesson in Skool

This page tells you what the number means and the order to act in. Skool is where it becomes a plan for your situation, read against your own labs.

  • The full Real Cardiovascular Risk protocol, step by step
  • Supplement form, timing and how long to run it
  • The hormones and compounds that move it, and what to watch
Join Skool $10/moCancel anytime

5.0 (15 reviews)1,500+ members

Coach Cam's community on Skool: the public page, with the rating, members and price

Want it built around you?

Educational and research purposes only. Not medical advice; talk to your clinician about results. Lab ranges vary by assay and laboratory: compare against the range printed on your own report. Some links are affiliate links; Cam may earn a commission at no extra cost to you. Medical disclaimer and affiliate disclosure

Order this testJoin Skool